Multicentre factorial randomized clinical trial of perioperative immunonutrition versus standard nutrition for patients undergoing surgical resection of oesophageal cancer. BJS 2018; 105: 1262-1272.
Published: 12th July 2018
Authors: L. A. Mudge, D. I. Watson, B. M. Smithers, E. A. Isenring, L. Smith, G. G. Jamieson et al.
Preoperative immunonutrition has been proposed to reduce the duration of hospital stay and infective complications following major elective surgery in patients with gastrointestinal malignancy. A multicentre 2 × 2 factorial RCT was conducted to determine the impact of preoperative and postoperative immunonutrition versus standard nutrition in patients with oesophageal cancer.
Patients were randomized before oesophagectomy to immunonutrition (IMPACT®) versus standard isocaloric/isonitrogenous nutrition, then further randomized after operation to immunonutrition versus standard nutrition. Clinical and quality‐of‐life outcomes were assessed at 14 and 42 days after operation on an intention‐to‐treat basis. The primary outcome was the occurrence of infective complications. Secondary outcomes were other complications, duration of hospital stay, mortality, nutritional and quality‐of‐life outcomes (EuroQol EQ‐5D‐3 L™, European Organisation for Research and Treatment of Cancer (EORTC) QLQ‐C30 and EORTC QLQ‐OES18). Patients and investigators were blinded until the completion of data analysis.
Some 278 patients from 11 Australian sites were randomized; two were excluded and data from 276 were analysed. The incidence of infective complications was similar for all groups (37 per cent in perioperative standard nutrition group, 51 per cent in perioperative immunonutrition group, 34 per cent in preoperative immunonutrition group and 40 per cent in postoperative immunonutrition group; P = 0·187). There were no significant differences in any other clinical or quality‐of‐life outcomes.
Use of immunonutrition before and/or after surgery provided no benefit over standard nutrition in patients undergoing oesophagectomy. Registration number: ACTRN12611000178943 (
You may also be interested in
Relationship between R1 resection, tumour rupture and recurrence in resected gastrointestinal stromal tumour.
Authors: T. Hølmebakk, B. Bjerkehagen, I. Hompland, S. Stoldt, K. Boye
Notes: Tumour rupture is most important
Effect of preoperative biliary drainage on cholestasis‐associated inflammatory and fibrotic gene signatures in perihilar cholangiocarcinoma. BJS 2019; 106: 55-58.
Authors: M. J. Reiniers, L. de Haan, R. Weijer, J. K. Wiggers, A. Jongejan, P. D. Moerland et al.
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
Authors: B.‐Y. Wang, S.‐C. Wu, H.‐C. Chen, W.‐H. Hung, C.‐H. Lin, C.‐L. Huang et al.
Notes: Surgery after chemoradiation indicated
Impact of postoperative complications on outcomes after oesophagectomy for cancer. BJS 2019; 106: 111-119.
Authors: L. Goense, J. Meziani, J. P. Ruurda, R. van Hillegersberg
Meta‐analysis of the influence of lifestyle changes for preoperative weight loss on surgical outcomes.
Authors: M. Roman, A. Monaghan, G. F. Serraino, D. Miller, S. Pathak, F. Lai et al.
Notes: Possible but how much is enough?
Multicentre cohort study of antihypertensive and lipid‐lowering therapy cessation after bariatric surgery.
Authors: J. Thereaux, T. Lesuffleur, S. Czernichow, A. Basdevant, S. Msika, D. Nocca et al.
Notes: Better than controls
Overall survival before and after centralization of gastric cancer surgery in the Netherlands. BJS 2018; 105: 1807-1815.
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practice makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus. BJS 2018; 105: 1793-1798.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Population‐based cohort study of diabetes mellitus and mortality in gastric adenocarcinoma. BJS 2018; 105: 1799-1806.
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk
Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. BJS 2018; 105: 1639-1649.
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
Notes: Nodal response predicts survival
Authors: H. Mackenzie, S. R. Markar, A. Askari, O. Faiz, M. Hull, S. Purkayastha et al.
Network meta‐analysis of surgical management of gastro‐oesophageal reflux disease in adults. BJS 2018; 105: 1398-1407.
Authors: M. A. Amer, M. D. Smith, C. H. Khoo, G. P. Herbison, J. L. McCall